ASH 2022: Leukemia

Test Your Knowledge from ASH on Leukemia!

Jan 30, 2023

Author

Rebecca Shover

View all posts

RETURN TO Test Your Knowledge from ASH on Leukemia!

MORE FROM ASH 2022: Leukemia

Excellent Results for Triplet Regimen in FLT3-Mutated AML

Dec 19, 2022

Ibrutinib Delays Need for Next Treatment in Real-World First-Line CLL

Dec 19, 2022

Blinatumomab Candidate for Standard-of-Care in Newly Diagnosed B-ALL

Dec 15, 2022

Novel Therapy May Replace Standard-of-Care Prophylaxis for GVHD

Dec 15, 2022

Intensive Chemotherapy Prior to Allo-HCT in Rel/Ref AML?

Dec 15, 2022

Ibrutinib Plus Venetoclax Displays Long-Term Benefits in CLL

Dec 15, 2022

ASH 2022: Leukemia

ASH 2022: Leukemia eBook

Focus on ASH Leukemia 2023.indd

Factors Associated With Improved COVID-19 Outcomes for CLL

Patients with chronic lymphocytic leukemia (CLL) infected with COVID-19 during the most recent phases of the pandemic had fewer hospitalizations,...

MRD by qPCR Prognostic of Outcomes in Venetoclax-Treated, NPM1-Mutated AML

Measurable/minimal residual disease (MRD) assessment by qPCR was strongly associated with clinical outcomes in patients with NPM1-mutated acute myeloid leukemia...

Follow Us

ASH 2022: Leukemia

Test Your Knowledge from ASH on Leukemia!

Author

MORE FROM ASH 2022: Leukemia

ASH 2022: Leukemia

PW Weekly Newsletters

MORE FROM ASH 2022: Leukemia

Stay connected to the latest news with Physician’s Weekly